Compare COFS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | LCTX |
|---|---|---|
| Founded | 1898 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.5M | 407.7M |
| IPO Year | 1995 | 1996 |
| Metric | COFS | LCTX |
|---|---|---|
| Price | $27.90 | $1.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $36.00 | $6.00 |
| AVG Volume (30 Days) | 79.7K | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $227,624,000.00 | $14,556,000.00 |
| Revenue This Year | $21.87 | $55.75 |
| Revenue Next Year | $4.47 | $2.96 |
| P/E Ratio | $13.61 | ★ N/A |
| Revenue Growth | ★ 63.64 | 53.24 |
| 52 Week Low | $24.89 | $0.37 |
| 52 Week High | $33.58 | $2.09 |
| Indicator | COFS | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 34.30 |
| Support Level | $26.10 | $0.94 |
| Resistance Level | $30.76 | $1.84 |
| Average True Range (ATR) | 1.00 | 0.10 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 38.40 | 9.82 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.